B+
Bull case
33%
Probability
Target price
$1.08
Analysis reference price unavailable
Analysis 2025-12-13 · RankAlpha Sentiment AI
DMAC
DiaMedica TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
33%
Probability
Target price
$0.57
Analysis reference price unavailable
Analysis 2025-12-13 · RankAlpha Sentiment AI
B-
Bear case
33%
Probability
Target price
$0.17
Analysis reference price unavailable
Analysis 2025-12-13 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2025-12-13
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
0.0
Score
AI commentary
Market tone is cautious-to-negative with primary focus on cash runway and binary trial outcomes; investors price in dilution risk while some speculative interest remains around licensing upside [#10-Qp12], [#PR-2025-09-12]. Overall headlines emphasize funding risk over near-term upside [#IR-press].
RankAlpha Sentiment AI - 2025-12-13
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-03-31eventPartnership or licensing dealHigh impact
A licensing agreement with a larger biopharma partner would de-risk development and likely produce a positive re-rate [#IR-press].
2026-03-31catalystCash runway / financing needHigh impact
Smaller biotechs commonly require dilutive financings; a negative financing event would drive a rapid downside [#10-Qp12].
2026-06-30eventClinical data readouts for lead programsHigh impact
Potential mid-stage or exploratory clinical readouts for DM199/DMA-001 could materially move valuation if efficacy/safety surprises [#10-Qp12], [#PR-2025-09-12].
Recommendation
N/A
No formal recommendation provided.
As of 2025-12-13 • Updated nightlySource: Internal modelMethodology